<DOC>
	<DOCNO>NCT00908986</DOCNO>
	<brief_summary>The objective study assess efficacy rituximab induction therapy membranous lupus nephritis . Safety tolerability additionally assess . Subjects receive open-label 2 course rituximab baseline 6 month . They follow monthly 18 month assess response durability response . The hypothesis : B cell depletion effective safe well tolerate treatment membranous lupus nephritis ( Class V ) .</brief_summary>
	<brief_title>Open Label Pilot Trial Rituximab Lupus Membranous Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age minimum 18 year old Able willing give write informed consent comply requirement study protocol Negative serum pregnancy test ( woman child bear potential ) Men woman reproductive potential must agree use acceptable method birth control treatment twelve month ( 1 year ) completion treatment . Diagnosis SLE per current ACR classification criterion ( least 4 11 criterion ) Base line proteinuria &gt; 2g/24h Kidney biopsy within 12 month enrollment membranous L.N . ( ISN/RPS V ) Full dose ACE inhibition ( ARB ) minimum 8 week day 0 . Patients may less full dose due lack tolerability Stable &lt; 0.5mg/kg corticosteroid dose 4 week prior screen ( include corticosteroid ) Background immunosuppressives include azathioprine , cyclosporine A , mycophenolate mofetil , methotrexate and/or antimalarial &gt; 6 month stable dose ( ) 1 month prior screening/enrollment allow . Patients receive cyclophosphamide and/or leflunomide exclude study . Treatment cyclophosphamide within 3 month screen Use high dose steroid ( &gt; 0.5 mg/kg/ day ) 4 week prior screen ANC &lt; 1.5 x 103 Hemoglobin : &lt; 8.0 gm/dL Platelets : &lt; 100,000/mm AST ALT &gt; 2.5 x Upper Limit Normal unless related primary disease . Positive Hepatitis B C serology ( Hep B Surface antigen Hep C antibody ) History positive HIV ( HIV conduct screen applicable ) Treatment investigational agent within 4 week screen 5 halflives investigational drug ( whichever longer ) Receipt live vaccine within 4 week prior randomization Previous Treatment Rituximab ( MabThera® / Rituxan® ) Previous treatment Natalizumab ( Tysabri® ) History severe allergic anaphylactic reaction humanize murine monoclonal antibody History recurrent significant infection history recurrent bacterial infection Known active bacterial , viral fungal mycobacterial , infection ( include tuberculosis atypical mycobacterial disease , exclude fungal infection nail bed ) major episode infection require hospitalization treatment i.v . antibiotic within 4 week screen oral antibiotic within 2 week prior screen Ongoing use high dose steroid ( &gt; 0.5 mg/kg/ day ) unstable steroid dose past 4 week Lack peripheral venous access History drug , alcohol , chemical abuse within 6 month prior screen Pregnancy ( negative serum pregnancy test perform woman childbearing potential within 7 day treatment ) lactation Concomitant malignancies previous malignancy , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix History psychiatric disorder would interfere normal participation protocol Significant cardiac pulmonary disease ( include obstructive pulmonary disease ) Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Lupus Membranous Nephritis</keyword>
</DOC>